Roche Taps Compugen to Seek Non-SNP Markers for Drug Response

Dec 21, 2007

NEW YORK (GenomeWeb News) – Compugen and Roche have agreed to collaborate in an effort to search for biomarkers that could help predict patient responses to drugs aimed at treating rheumatoid arthritis, Compugen said Thursday.

Compugen will use its GeneVa database, which holds around 200,000 non-SNP genetic variations, to investigate DNA samples for markers that could predict response or non-response to selected drugs Roche intends to develop.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Privacy Policy Information, Please

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

Moving the Parts About

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

This Week in Science

In Science this week: genetic overlap among many psychiatric disorders, and more.

Just Skip that Step

The Economist writes that an increasing number of scientific journals don't do peer review.

Main menu